Yet an­oth­er NASH de­feat for Gilead as 3-drug cock­tail fiz­zles. Now one an­a­lyst says it's time for a change-up

3 years ago
R&D

Wave's Duchenne pro­gram comes to a screech­ing halt — now all eyes will be on Hunt­ing­ton's

3 years ago
R&D

Paul Bion­di is jump­ing from Bris­tol-My­ers to the elite team man­ag­ing Flag­ship's star­tups — with new­co plans of his own

3 years ago
R&D

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nals big trou­ble for a lit­tle biotech

3 years ago
R&D

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

3 years ago
Cell/Gene Tx

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

3 years ago
Pharma
FDA+

What's next for Sarep­ta? A third DMD ap­proval, an­a­lysts pre­dict

3 years ago
FDA+

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

3 years ago
R&D
FDA+

Bris­tol-My­er­s' strat­e­gy, BD chief Paul Bion­di ex­it­ed the com­pa­ny — just ahead of the $74B Cel­gene deal close

3 years ago
People

Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

3 years ago
Cell/Gene Tx

On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to the fin­ish line

3 years ago
R&D

For sale: Long-act­ing PhI­II GLP-1 di­a­betes drug that’s way be­hind ri­vals, now spurned by Sanofi

3 years ago
R&D

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

3 years ago
R&D

Bris­tol-My­ers shows off a low-pro­file AML con­tender it gained from Cel­gene buy­out — and they’re tak­ing it straight to the FDA

3 years ago
R&D

New trade deal knocks out long-sought bi­o­log­ics pro­tec­tions for drug­mak­ers

3 years ago
R&D

Af­ter sev­er­al high pro­file start­up launch­es, om­niv­o­rous Omega Funds clos­es $438M fund to pur­sue more deals

3 years ago
Financing

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

3 years ago
R&D

Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

3 years ago
R&D

In a play-by-play of the $9.7B Med­Co buy­out, No­var­tis ad­mits it over­paid while of­fer­ing a huge wind­fall to ex­ecs

3 years ago
Deals

Roche faces an­oth­er de­lay in strug­gle to nav­i­gate Spark deal past reg­u­la­tors — but this one is very short

3 years ago
R&D

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

3 years ago
R&D

New Sanofi CEO Hud­son adds next-gen can­cer drug tech to the R&D quest, buy­ing Syn­thorx for $2.5B

3 years ago
Deals

Pa­tient #9 has been a con­cern, but Sang­amo and Pfiz­er are bull­ish about win­ning the marathon he­mo­phil­ia A gene ther­a­py race

3 years ago
R&D
Cell/Gene Tx

J&J team shows off 'break­through' BC­MA CAR-T da­ta, and that could cause a big headache at blue­bird and Bris­tol-My­ers

3 years ago
R&D
Cell/Gene Tx
First page Previous page 117118119120121122123 Next page Last page